Ken Griffin Protalix Bio Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$1.22 - $1.82 $81,618 - $121,758	-66,900 Reduced 83.94%	12,800 $16,000
Q4 2023 Feb 14, 2024	BUY	$1.34 - $1.85 $39,128 - $54,020	29,200 Added 57.82%	79,700 $141,000
Q3 2023 Nov 14, 2023	SELL	$1.49 - $2.02 $125,160 - $169,680	-84,000 Reduced 62.45%	50,500 $83,000
Q2 2023 Aug 14, 2023	BUY	$2.0 - $3.36 $85,200 - $143,136	42,600 Added 46.35%	134,500 $269,000
Q1 2023 May 15, 2023	BUY	$1.37 - $2.16 $55,759 - $87,912	40,700 Added 79.49%	91,900 $192,000

Q4 2022 Feb 14, 2023	BUY	$1.02 - $1.37 $7,446 - $10,001	7,300 Added 16.63%	51,200 $70,000
Q3 2022 Nov 14, 2022	SELL	$1.03 - $1.24 $6,489 - $7,812	-6,300 Reduced 12.55%	43,900 $46,000

9.27M

40.6K

10.1K

Ticker PLX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,753,400
Market Cap $55.7M
Description
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.